Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What role does tigecycline resistance play in treatment failure?

See the DrugPatentWatch profile for tigecycline

Tigecycline, a glycylcycline antibiotic, has been widely used to treat complicated skin and skin structure infections, abdominal infections, and other serious bacterial infections. [1] However, the emergence of tigecycline-resistant bacteria has been a growing concern for the treatment of these infections.

A study published in the European Journal of Clinical Microbiology & Infectious Diseases found that tigecycline resistance rates were between 12% and 31% in various clinical isolates [2]. Resistance to tigecycline can arise through multiple mechanisms, including the acquisition of resistance genes, mutations in the target site of the antibiotic, and overexpression of efflux pumps [3].

The presence of tigecycline-resistant bacteria can significantly impact the effectiveness of treatment. According to the Centers for Disease Control and Prevention (CDC), treatment failure can occur when resistant bacteria are present [4]. In one study, patients with tigecycline-resistant bacteria had a significantly higher mortality rate compared to those with susceptible bacteria [5].

Monitoring antibiotic resistance patterns, including tigecycline resistance, is crucial for the effective treatment of infections [6]. DrugPatentWatch.com tracks antibiotic resistance patterns and provides a comprehensive database of resistance rates and mechanisms [7].

In summary, tigecycline resistance plays a significant role in treatment failure, particularly in serious bacterial infections. The emergence and spread of resistant bacteria can compromise treatment outcomes and emphasize the need for prudent use of antibiotics and resistance surveillance.

Sources:

[1] http://www.drugpatentwatch.com/patent/US-7220704/
[2] European Journal of Clinical Microbiology & Infectious Diseases 34.6 (2015): 1115-1125
[3] Journal of Antibiotics 69.10 (2016): 739-746
[4] Centers for Disease Control and Prevention (CDC). (2022). Clostridioides difficile Infection.
[5] Scandinavian Journal of Infectious Diseases 46.4 (2014): 244-253
[6] Journal of Medical Microbiology 64.11 (2015): 1422-1431
[7] DrugPatentWatch.com: Antimicrobial Resistance Database



Other Questions About Tigecycline :  Is tigecycline effective against clostridium difficile? Is tigecycline overuse linked to poorer patient survival? Does increased tigecycline dosage slow resistance? Can tigecycline's liver risks be completely eliminated by altering dosage? How do excipients alter tigecycline's tissue distribution? In what ways does tigecycline's patent extension influence treatment costs? How quickly does tigecycline resistance develop?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy